PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
25803806-3	2015	The in vivo Weibel-Palade body secretagogue, des-amino-D-arginine vasopressin (DDAVP), would be expected to increase transiently the circulating factor H levels, in addition to increasing the circulating levels of VWF.	Deamino Arginine Vasopressin	79-84	arginine vasopressin	Homo sapiens	66-77
26062878-6	2015	Estradiol treatment of mpkCCD cells reduced AQP2 at both the mRNA and protein level in the absence of deamino-8-d-AVP (dDAVP) and significantly blunted the dDAVP-induced increase in AQP2 at the protein level only.	Deamino Arginine Vasopressin	156-161	aquaporin 2	Mus musculus	182-186
26536898-6	2016	ACTH-dependent hypercortisolism was diagnosed based on the results of the 0.5 mg dexamethasone suppression test (serum cortisol >3.0 mug/dL) plus one positive finding of the following two tests: midnight serum cortisol level >5.0 mug/dL or ACTH increase >50% after 1-deamino-5-D-arginine vasopressin (DDAVP) challenge.	Deamino Arginine Vasopressin	310-315	proopiomelanocortin	Homo sapiens	0-4
25803806-3	2015	The in vivo Weibel-Palade body secretagogue, des-amino-D-arginine vasopressin (DDAVP), would be expected to increase transiently the circulating factor H levels, in addition to increasing the circulating levels of VWF.	Deamino Arginine Vasopressin	79-84	complement factor H	Homo sapiens	145-153
25803806-3	2015	The in vivo Weibel-Palade body secretagogue, des-amino-D-arginine vasopressin (DDAVP), would be expected to increase transiently the circulating factor H levels, in addition to increasing the circulating levels of VWF.	Deamino Arginine Vasopressin	79-84	von Willebrand factor	Homo sapiens	214-217
25803806-9	2015	DDAVP induces the secretion into human plasma of VWF--but not factor H.	Deamino Arginine Vasopressin	0-5	von Willebrand factor	Homo sapiens	49-52
15513933-2	2005	In this study, we used the short-circuit current (I(sc)) method to investigate the effects of deamino-8-d-arginine vasopressin (dDAVP) on Na(+) and Cl(-) fluxes in primary cultures of cortical collecting ducts (CCDs) microdissected from the kidneys of mice with Liddle"s syndrome carrying a stop codon mutation, corresponding to the beta-ENaC R(566) stop mutation (L) found in the original pedigree.	Deamino Arginine Vasopressin	128-133	sodium channel, nonvoltage-gated 1 beta	Mus musculus	333-342
24782621-4	2014	Total and membrane NKCC2 expression in the colonic mucosa from control and dDAVP-treated mice was detected by Western blotting.	Deamino Arginine Vasopressin	75-80	solute carrier family 12, member 1	Mus musculus	19-24
24782621-7	2014	Short-term treatment with dDAVP, a V2-type receptor-specific vasopressin analog, induced NKCC2 re-distribution, i.e., NKCC2 traffics to the apical membrane after dDAVP stimulation.	Deamino Arginine Vasopressin	26-31	solute carrier family 12, member 1	Mus musculus	89-94
24782621-7	2014	Short-term treatment with dDAVP, a V2-type receptor-specific vasopressin analog, induced NKCC2 re-distribution, i.e., NKCC2 traffics to the apical membrane after dDAVP stimulation.	Deamino Arginine Vasopressin	26-31	solute carrier family 12, member 1	Mus musculus	118-123
24782621-7	2014	Short-term treatment with dDAVP, a V2-type receptor-specific vasopressin analog, induced NKCC2 re-distribution, i.e., NKCC2 traffics to the apical membrane after dDAVP stimulation.	Deamino Arginine Vasopressin	162-167	solute carrier family 12, member 1	Mus musculus	89-94
24782621-7	2014	Short-term treatment with dDAVP, a V2-type receptor-specific vasopressin analog, induced NKCC2 re-distribution, i.e., NKCC2 traffics to the apical membrane after dDAVP stimulation.	Deamino Arginine Vasopressin	162-167	solute carrier family 12, member 1	Mus musculus	118-123
24782621-9	2014	Western blotting results confirmed that membrane NKCC2 had significantly higher abundance in the dDAVP-treated mouse colonic mucosa relative to that in the untreated control, which is consistent with our immunostaining data.	Deamino Arginine Vasopressin	97-102	solute carrier family 12, member 1	Mus musculus	49-54
20668095-6	2010	UT-A1 mRNA and protein abundance were significantly increased in the medullas of wild-type and AQP1KO mice following dDAVP infusion.	Deamino Arginine Vasopressin	117-122	solute carrier family 14 (urea transporter), member 2	Mus musculus	0-5
20668095-7	2010	The mRNA and protein abundance of UT-A3, the basolateral urea transporter, was significantly increased by dDAVP in both wild-type and AQP1KO mice.	Deamino Arginine Vasopressin	106-111	solute carrier family 14 (urea transporter), member 2	Mus musculus	34-39
20668095-8	2010	Semiquantitative immunoblots revealed that dDAVP infusion induced a significant increase in the medullary expression of the endoplasmic reticulum (ER) chaperone GRP78.	Deamino Arginine Vasopressin	43-48	heat shock protein 5	Mus musculus	161-166
20668095-11	2010	Urea-sensitive genes, GADD153 and ATF4 (components of the ER stress pathway), were significantly increased in AQP1KO mice by dDAVP infusion.	Deamino Arginine Vasopressin	125-130	DNA-damage inducible transcript 3	Mus musculus	22-29
20668095-11	2010	Urea-sensitive genes, GADD153 and ATF4 (components of the ER stress pathway), were significantly increased in AQP1KO mice by dDAVP infusion.	Deamino Arginine Vasopressin	125-130	activating transcription factor 4	Mus musculus	34-38
20445498-6	2010	dDAVP significantly increased the abundance of phosphorylated STE20/SPS1-related proline-alanine-rich kinase and oxidative stress-response kinase (SPAK and OSR1), kinases implicated in NCC phosphorylation.	Deamino Arginine Vasopressin	0-5	serine threonine kinase 39	Rattus norvegicus	147-151
20445498-6	2010	dDAVP significantly increased the abundance of phosphorylated STE20/SPS1-related proline-alanine-rich kinase and oxidative stress-response kinase (SPAK and OSR1), kinases implicated in NCC phosphorylation.	Deamino Arginine Vasopressin	0-5	odd-skipped related transcription factor 1	Rattus norvegicus	156-160
18680527-6	2008	Following intravenous DDAVP, 0.3 mug kg(-1), on day 7 there was a further boost in VWF and FVIII levels, suggesting that the mechanism of rhIL-11 differs from that of DDAVP.	Deamino Arginine Vasopressin	22-27	von Willebrand factor	Homo sapiens	83-86
18680527-6	2008	Following intravenous DDAVP, 0.3 mug kg(-1), on day 7 there was a further boost in VWF and FVIII levels, suggesting that the mechanism of rhIL-11 differs from that of DDAVP.	Deamino Arginine Vasopressin	22-27	coagulation factor VIII	Homo sapiens	91-96
21898084-13	2012	Low ADH levels were recognized as a possible cause of PNE, thereby explaining the good response to DDAVP treatment in Taiwanese children with PNE.	Deamino Arginine Vasopressin	99-104	arginine vasopressin	Homo sapiens	4-7
22834326-5	2012	Fourteen patients with affective disorders have been treated with subendocrine doses of 1-desamino-8-D-arginin-vasopressin (DDAVP) daily by intranasal application during 1,5-2 months.	Deamino Arginine Vasopressin	124-129	arginine vasopressin	Homo sapiens	111-122
22834326-8	2012	The results of this pilot study demonstrate perspective of using selective agonist of vasopressin V2 receptors, DDAVP, in therapy of post-stroke depression.	Deamino Arginine Vasopressin	112-117	arginine vasopressin	Homo sapiens	86-97
16609148-7	2006	Consistent with the known effects of vasopressin, administration of DDAVP caused a decrease in V2R mRNA levels and an increase in AQP2 mRNA levels in both TG and non-TG animals, suggesting an appropriate renal response to DDAVP in the TG mice.	Deamino Arginine Vasopressin	68-73	aquaporin 2	Mus musculus	130-134
15347643-5	2004	32P incubation of the inner medulla followed by autoradiography of two-dimensional gels demonstrated increased 32P labeling of both isoforms in response to the V2 receptor agonist [deamino-Cys1,D-Arg8]vasopressin (DDAVP).	Deamino Arginine Vasopressin	214-219	arginine vasopressin	Rattus norvegicus	201-212
15347643-7	2004	The MLCK inhibitor ML-7 blocked the DDAVP-induced MLC phosphorylation and substantially reduced [Arg8]vasopressin (AVP)-stimulated water permeability.	Deamino Arginine Vasopressin	36-41	myosin light chain kinase	Rattus norvegicus	4-8
15198931-10	2004	Thus it was suggested that dDAVP may induce uPA release from human lymphocytes via V(2) receptor-mediated reaction, and also via cross-talk between V(1) and V(2) receptors.	Deamino Arginine Vasopressin	27-32	plasminogen activator, urokinase	Homo sapiens	44-47
15198931-0	2004	Induction of uPA release in human peripheral blood lymphocytes by [deamino-Cysl,D-Arg8]-vasopressin (dDAVP).	Deamino Arginine Vasopressin	101-106	plasminogen activator, urokinase	Homo sapiens	13-16
12709058-5	2003	[deamino-Cys1, d-Arg8]-vasopressin (DDAVP), a specific V2 receptor agonist, increased the surface level of P-LAP, while [adamantaneacetyl1, O-Et-d-Tyr2, Val4, aminobutyryl6, Arg8,9]-vasopressin (AEAVP), a potent V2 receptor antagonist, blocked the AVP-stimulated enhancement.	Deamino Arginine Vasopressin	36-41	leucyl and cystinyl aminopeptidase	Rattus norvegicus	107-112
15513933-6	2005	I(sc) recordings performed under apical ion substituted conditions revealed that the dDAVP-stimulated apical secretion of Cl(-), which was absent in cultured CCDs lacking CFTR, was 1.8-fold greater in L/+ and 3.7-fold greater in L/L CCD cells than in their +/+ CCD counterparts.	Deamino Arginine Vasopressin	85-90	cystic fibrosis transmembrane conductance regulator	Mus musculus	171-175
15377475-6	2004	RESULTS: After 1-deamino-8-D-argine vasopressin (DDAVP) infusion, factor VIII and VWF activities increased and HMW VWF multimers were transiently observed in the patient"s plasma.	Deamino Arginine Vasopressin	49-54	von Willebrand factor	Homo sapiens	82-85
15377475-6	2004	RESULTS: After 1-deamino-8-D-argine vasopressin (DDAVP) infusion, factor VIII and VWF activities increased and HMW VWF multimers were transiently observed in the patient"s plasma.	Deamino Arginine Vasopressin	49-54	von Willebrand factor	Homo sapiens	115-118
11782489-4	2002	The stimulatory effect of AVP on AQP2 expression followed a V(2) receptor-dependent pathway because [deamino-8-d-arginine]vasopressin (dDAVP), a specific V(2) receptor agonist, produced the same effect as AVP, whereas the V(2) antagonist SR121463B antagonized action of both AVP and dDAVP.	Deamino Arginine Vasopressin	135-140	aquaporin 2	Mus musculus	33-37
12553551-2	2002	The aim of the current study was to evaluate baseline and CRH-stimulated ACTH and F levels in patients with central diabetes insipidus (CDI), before and after replacement therapy with desamino-D-AVP (DDAVP).	Deamino Arginine Vasopressin	200-205	corticotropin releasing hormone	Homo sapiens	58-61
12553551-9	2002	In addition, replacement treatment with DDAVP normalized CRH-induced but not baseline ACTH and F secretion.	Deamino Arginine Vasopressin	40-45	corticotropin releasing hormone	Homo sapiens	57-60
11782489-4	2002	The stimulatory effect of AVP on AQP2 expression followed a V(2) receptor-dependent pathway because [deamino-8-d-arginine]vasopressin (dDAVP), a specific V(2) receptor agonist, produced the same effect as AVP, whereas the V(2) antagonist SR121463B antagonized action of both AVP and dDAVP.	Deamino Arginine Vasopressin	283-288	aquaporin 2	Mus musculus	33-37
11563592-7	2001	The increase in the collagen-binding activity of VWF released in type 1 VWD patients (n=7) after treatment with DDAVP was higher than the increase in the VWF antigen; this is characteristic of very high multimers with greater functional activity.	Deamino Arginine Vasopressin	112-117	von Willebrand factor	Homo sapiens	49-52
11813892-6	2001	1-Deamino-D-arginine vasopressin (DDAVP; 10(-8) M; n = 5) and 8-bromo-cAMP (10(-4) M; n = 5) also mimicked the effect of AVP with similar time courses.	Deamino Arginine Vasopressin	34-39	arginine vasopressin	Rattus norvegicus	21-32
11813892-9	2001	Our results demonstrate that AVP increases the IKs channel current in marginal cells of the neonatal rat at a concentration of 10(-8) M, and the fact that 8-bromo-cAMP (10(-4) M) and DDAVP (10(-8) M) also showed similar effects at 24 degrees C may suggest the involvement of V2 receptors and the subsequent activation of the cAMP signal pathway.	Deamino Arginine Vasopressin	183-188	arginine vasopressin	Rattus norvegicus	29-32
11502593-3	2001	dDAVP stimulated the benzamyl amiloride (BAm)-sensitive transport of Na(+) assessed by the short-circuit current (I(sc)) method in both CFTR(+/+) and CFTR(-/-) CCDs to a very similar degree.	Deamino Arginine Vasopressin	0-5	cystic fibrosis transmembrane conductance regulator	Mus musculus	136-140
11502593-3	2001	dDAVP stimulated the benzamyl amiloride (BAm)-sensitive transport of Na(+) assessed by the short-circuit current (I(sc)) method in both CFTR(+/+) and CFTR(-/-) CCDs to a very similar degree.	Deamino Arginine Vasopressin	0-5	cystic fibrosis transmembrane conductance regulator	Mus musculus	150-154
11502593-4	2001	Apical addition of 5-nitro-2-(3-phenylpropylamino)-benzoate (NPPB) or glibenclamide partially inhibited the rise in I(sc) induced by dDAVP and ISO in BAm-treated CFTR(+/+) CCDs, whereas dDAVP, ISO, and NPPB did not alter I(sc) in BAm-treated CFTR(-/-) CCDs.	Deamino Arginine Vasopressin	133-138	cystic fibrosis transmembrane conductance regulator	Mus musculus	162-166
11502593-4	2001	Apical addition of 5-nitro-2-(3-phenylpropylamino)-benzoate (NPPB) or glibenclamide partially inhibited the rise in I(sc) induced by dDAVP and ISO in BAm-treated CFTR(+/+) CCDs, whereas dDAVP, ISO, and NPPB did not alter I(sc) in BAm-treated CFTR(-/-) CCDs.	Deamino Arginine Vasopressin	133-138	cystic fibrosis transmembrane conductance regulator	Mus musculus	242-246
11502593-5	2001	dDAVP stimulated the apical-to-basal flux and, to a lesser extent, the basal-to-apical flux of (36)Cl(-) in CFTR(+/+) CCDs.	Deamino Arginine Vasopressin	0-5	cystic fibrosis transmembrane conductance regulator	Mus musculus	108-112
11502593-6	2001	dDAVP also increased the apical-to-basal (36)Cl(-) flux in CFTR(-/-) CCDs but not the basal-to-apical (36)Cl(-) flux.	Deamino Arginine Vasopressin	0-5	cystic fibrosis transmembrane conductance regulator	Mus musculus	59-63
11260278-7	2001	In an individual with type 2A vWD, DDAVP normalized vWF:Ag and vWF:RCof, but had no apparent effect on the baseline maximally prolonged CT.	Deamino Arginine Vasopressin	35-40	von Willebrand factor	Homo sapiens	52-55
11336804-10	2001	The PKC inhibitor chelerythrine significantly reduced PLD activation by dDAVP, CPA and 8Br-cAMP, without changing the effect of ATP.	Deamino Arginine Vasopressin	72-77	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	54-57
11260278-7	2001	In an individual with type 2A vWD, DDAVP normalized vWF:Ag and vWF:RCof, but had no apparent effect on the baseline maximally prolonged CT.	Deamino Arginine Vasopressin	35-40	von Willebrand factor	Homo sapiens	63-66
11260278-12	2001	Furthermore, the combined utility of the PFA-100 and vWF:CBA as markers of DDAVP responsiveness may prove to be simple, quick but powerful, predictors for its clinical efficacy.	Deamino Arginine Vasopressin	75-80	von Willebrand factor	Homo sapiens	41-56
11053048-10	2000	Quantitative analysis of labeling was consistent with expression of AQP2 over a longer region of CNT after dDAVP exposure.	Deamino Arginine Vasopressin	107-112	aquaporin 2	Rattus norvegicus	68-72
11158395-6	2001	The rise in I(sc) caused by dDAVP (10(-8) M) was inhibited by amiloride, and to a lesser extent by 5-nitro-2-(3-phenylpropylamino)-benzoic acid (NPPB) in all three cell lines.	Deamino Arginine Vasopressin	28-33	natriuretic peptide type B	Mus musculus	145-149
11158395-7	2001	The dDAVP-dependent I(sc) measured under apical Na(+)-free condition was reduced by Cl(-) channel blockers with a profile (NPPB>glibenclamide>DIDS), similar to that for rat CFTR.	Deamino Arginine Vasopressin	4-9	natriuretic peptide B	Rattus norvegicus	123-127
11158395-7	2001	The dDAVP-dependent I(sc) measured under apical Na(+)-free condition was reduced by Cl(-) channel blockers with a profile (NPPB>glibenclamide>DIDS), similar to that for rat CFTR.	Deamino Arginine Vasopressin	4-9	CF transmembrane conductance regulator	Rattus norvegicus	179-183
11026555-7	2000	Dose dependent stimulation of cells expressing the T204N mutant with AVP and with the therapeutic AVP analogue 1-deamino[D-Arg8]vasopressin (dDAVP) revealed that AVP was 50-fold more potent than dDAVP.	Deamino Arginine Vasopressin	141-146	arginine vasopressin	Homo sapiens	98-101
11026555-7	2000	Dose dependent stimulation of cells expressing the T204N mutant with AVP and with the therapeutic AVP analogue 1-deamino[D-Arg8]vasopressin (dDAVP) revealed that AVP was 50-fold more potent than dDAVP.	Deamino Arginine Vasopressin	141-146	arginine vasopressin	Homo sapiens	128-139
11026555-7	2000	Dose dependent stimulation of cells expressing the T204N mutant with AVP and with the therapeutic AVP analogue 1-deamino[D-Arg8]vasopressin (dDAVP) revealed that AVP was 50-fold more potent than dDAVP.	Deamino Arginine Vasopressin	141-146	arginine vasopressin	Homo sapiens	98-101
11026555-7	2000	Dose dependent stimulation of cells expressing the T204N mutant with AVP and with the therapeutic AVP analogue 1-deamino[D-Arg8]vasopressin (dDAVP) revealed that AVP was 50-fold more potent than dDAVP.	Deamino Arginine Vasopressin	195-200	arginine vasopressin	Homo sapiens	98-101
11026555-7	2000	Dose dependent stimulation of cells expressing the T204N mutant with AVP and with the therapeutic AVP analogue 1-deamino[D-Arg8]vasopressin (dDAVP) revealed that AVP was 50-fold more potent than dDAVP.	Deamino Arginine Vasopressin	195-200	arginine vasopressin	Homo sapiens	98-101
9636246-8	1998	These results suggest that the discrete dDAVP-elicited Cl- secretion involves the CFTR and that dDAVP and aldosterone may affect in different ways the observed increased Cl- reabsorption in this model of mouse cultured cortical collecting duct cells.	Deamino Arginine Vasopressin	40-45	cystic fibrosis transmembrane conductance regulator	Mus musculus	82-86
9841509-2	1998	Here, we show that isolated perfused inner medullary collecting ducts (IMCDs) from vasopressin-escape rats desamino-[D-arginine]vasopressin (DDAVP)/water-loaded have dramatically reduced vasopressin-dependent osmotic water permeabilities [46% of control rats (DDAVP alone)], which coincides with a fall in inner medullary aquaporin-2 protein abundance as measured by immunoblotting in the opposite kidney.	Deamino Arginine Vasopressin	141-146	arginine vasopressin	Rattus norvegicus	83-94
9841509-2	1998	Here, we show that isolated perfused inner medullary collecting ducts (IMCDs) from vasopressin-escape rats desamino-[D-arginine]vasopressin (DDAVP)/water-loaded have dramatically reduced vasopressin-dependent osmotic water permeabilities [46% of control rats (DDAVP alone)], which coincides with a fall in inner medullary aquaporin-2 protein abundance as measured by immunoblotting in the opposite kidney.	Deamino Arginine Vasopressin	141-146	arginine vasopressin	Rattus norvegicus	128-139
9841509-2	1998	Here, we show that isolated perfused inner medullary collecting ducts (IMCDs) from vasopressin-escape rats desamino-[D-arginine]vasopressin (DDAVP)/water-loaded have dramatically reduced vasopressin-dependent osmotic water permeabilities [46% of control rats (DDAVP alone)], which coincides with a fall in inner medullary aquaporin-2 protein abundance as measured by immunoblotting in the opposite kidney.	Deamino Arginine Vasopressin	141-146	arginine vasopressin	Rattus norvegicus	128-139
9841509-2	1998	Here, we show that isolated perfused inner medullary collecting ducts (IMCDs) from vasopressin-escape rats desamino-[D-arginine]vasopressin (DDAVP)/water-loaded have dramatically reduced vasopressin-dependent osmotic water permeabilities [46% of control rats (DDAVP alone)], which coincides with a fall in inner medullary aquaporin-2 protein abundance as measured by immunoblotting in the opposite kidney.	Deamino Arginine Vasopressin	141-146	aquaporin 2	Rattus norvegicus	322-333
9841509-2	1998	Here, we show that isolated perfused inner medullary collecting ducts (IMCDs) from vasopressin-escape rats desamino-[D-arginine]vasopressin (DDAVP)/water-loaded have dramatically reduced vasopressin-dependent osmotic water permeabilities [46% of control rats (DDAVP alone)], which coincides with a fall in inner medullary aquaporin-2 protein abundance as measured by immunoblotting in the opposite kidney.	Deamino Arginine Vasopressin	260-265	arginine vasopressin	Rattus norvegicus	83-94
9841509-2	1998	Here, we show that isolated perfused inner medullary collecting ducts (IMCDs) from vasopressin-escape rats desamino-[D-arginine]vasopressin (DDAVP)/water-loaded have dramatically reduced vasopressin-dependent osmotic water permeabilities [46% of control rats (DDAVP alone)], which coincides with a fall in inner medullary aquaporin-2 protein abundance as measured by immunoblotting in the opposite kidney.	Deamino Arginine Vasopressin	260-265	arginine vasopressin	Rattus norvegicus	128-139
9841509-2	1998	Here, we show that isolated perfused inner medullary collecting ducts (IMCDs) from vasopressin-escape rats desamino-[D-arginine]vasopressin (DDAVP)/water-loaded have dramatically reduced vasopressin-dependent osmotic water permeabilities [46% of control rats (DDAVP alone)], which coincides with a fall in inner medullary aquaporin-2 protein abundance as measured by immunoblotting in the opposite kidney.	Deamino Arginine Vasopressin	260-265	arginine vasopressin	Rattus norvegicus	128-139
9841509-3	1998	Furthermore, we demonstrate in IMCD suspensions that cAMP accumulation in response to DDAVP is substantially reduced in the vasopressin-escape rats both in the presence and absence of the phosphodiesterase inhibitor IBMX.	Deamino Arginine Vasopressin	86-91	arginine vasopressin	Rattus norvegicus	124-135
9572997-13	1998	These results indicate that patients with AvWS developing inhibitors to vWF are likely to have bleeding problems and might be resistant to treatment of underlying diseases and/or therapy with DDAVP for bleeding to AvWS.	Deamino Arginine Vasopressin	192-197	von Willebrand factor	Homo sapiens	72-75
8593805-10	1996	Correction of the diabetes insipidus by DDAVP treatment further decreased hypothalamic VP mRNA levels, but restored CRH mRNA to control levels.	Deamino Arginine Vasopressin	40-45	corticotropin releasing hormone	Rattus norvegicus	116-119
9294826-1	1997	Previous studies by the authors demonstrated that the response of urinary aquaporin-2 (AQP2) excretion to dDAVP (deamino-8-D-arginine vasopressin) infusion is an index of vasopressin action on the kidney (N Engl J Med 332: 1540-1545, 1995).	Deamino Arginine Vasopressin	106-111	aquaporin 2	Homo sapiens	74-85
9294826-1	1997	Previous studies by the authors demonstrated that the response of urinary aquaporin-2 (AQP2) excretion to dDAVP (deamino-8-D-arginine vasopressin) infusion is an index of vasopressin action on the kidney (N Engl J Med 332: 1540-1545, 1995).	Deamino Arginine Vasopressin	106-111	aquaporin 2	Homo sapiens	87-91
9294826-1	1997	Previous studies by the authors demonstrated that the response of urinary aquaporin-2 (AQP2) excretion to dDAVP (deamino-8-D-arginine vasopressin) infusion is an index of vasopressin action on the kidney (N Engl J Med 332: 1540-1545, 1995).	Deamino Arginine Vasopressin	106-111	arginine vasopressin	Homo sapiens	134-145
9294826-1	1997	Previous studies by the authors demonstrated that the response of urinary aquaporin-2 (AQP2) excretion to dDAVP (deamino-8-D-arginine vasopressin) infusion is an index of vasopressin action on the kidney (N Engl J Med 332: 1540-1545, 1995).	Deamino Arginine Vasopressin	106-111	arginine vasopressin	Homo sapiens	171-182
8178313-1	1994	DDAVP, an analog of vasopressin, has been shown to have hemostatic activity.	Deamino Arginine Vasopressin	0-5	arginine vasopressin	Rattus norvegicus	20-31
7893933-6	1994	Furthermore DDAVP normalized FVIII, von Willebrand factor (vWf) antigen (vWf:Ag), and to a lesser extent, vWf ristocetin cofactor activity (vWf:RCoF).	Deamino Arginine Vasopressin	12-17	coagulation factor VIII	Homo sapiens	29-34
7893933-6	1994	Furthermore DDAVP normalized FVIII, von Willebrand factor (vWf) antigen (vWf:Ag), and to a lesser extent, vWf ristocetin cofactor activity (vWf:RCoF).	Deamino Arginine Vasopressin	12-17	von Willebrand factor	Homo sapiens	36-57
7893933-6	1994	Furthermore DDAVP normalized FVIII, von Willebrand factor (vWf) antigen (vWf:Ag), and to a lesser extent, vWf ristocetin cofactor activity (vWf:RCoF).	Deamino Arginine Vasopressin	12-17	von Willebrand factor	Homo sapiens	59-62
7893933-6	1994	Furthermore DDAVP normalized FVIII, von Willebrand factor (vWf) antigen (vWf:Ag), and to a lesser extent, vWf ristocetin cofactor activity (vWf:RCoF).	Deamino Arginine Vasopressin	12-17	von Willebrand factor	Homo sapiens	73-76
7893933-6	1994	Furthermore DDAVP normalized FVIII, von Willebrand factor (vWf) antigen (vWf:Ag), and to a lesser extent, vWf ristocetin cofactor activity (vWf:RCoF).	Deamino Arginine Vasopressin	12-17	von Willebrand factor	Homo sapiens	73-76
7893933-6	1994	Furthermore DDAVP normalized FVIII, von Willebrand factor (vWf) antigen (vWf:Ag), and to a lesser extent, vWf ristocetin cofactor activity (vWf:RCoF).	Deamino Arginine Vasopressin	12-17	von Willebrand factor	Homo sapiens	73-76
7910971-2	1994	A dose-dependent t-PA release from the isolated perfused vascular preparations may be induced by mediators (platelet-activating factor, bradykinin, histamine) adrenergic and cholinergic transmitters (isoprenaline, acetylcholine), thrombin, heparin and analogues, and 1-desamino-8-D-arginine-vasopression (DDAVP).	Deamino Arginine Vasopressin	305-310	plasminogen activator, tissue type	Rattus norvegicus	17-21
8322282-0	1993	Repeated infusions of DDAVP induce low response of FVIII and vWF but not of plasminogen activators.	Deamino Arginine Vasopressin	22-27	coagulation factor VIII	Homo sapiens	51-56
8190753-0	1994	The abnormal quinine drinking aversion in the Brattleboro rat with diabetes insipidus is reversed by the vasopressin agonist DDAVP: a possible role for vasopressin in the motivation to drink.	Deamino Arginine Vasopressin	125-130	arginine vasopressin	Rattus norvegicus	105-116
8190753-0	1994	The abnormal quinine drinking aversion in the Brattleboro rat with diabetes insipidus is reversed by the vasopressin agonist DDAVP: a possible role for vasopressin in the motivation to drink.	Deamino Arginine Vasopressin	125-130	arginine vasopressin	Rattus norvegicus	152-163
8190753-3	1994	Acute or chronic treatment of BDI rats with desamino-8D arginine vasopressin (DDAVP) restored to normal their drinking response to quinine solution.	Deamino Arginine Vasopressin	78-83	arginine vasopressin	Rattus norvegicus	65-76
8190753-6	1994	These results suggest that the abnormal drinking response to quinine-adulterated fluid in BDI rats is reversed by treatment with the vasopressin V2-receptor agonist DDAVP but is unlikely to be a consequence of the restoration of fluid turnover to normal levels by a renal action.	Deamino Arginine Vasopressin	165-170	arginine vasopressin receptor 2	Rattus norvegicus	133-156
8322282-0	1993	Repeated infusions of DDAVP induce low response of FVIII and vWF but not of plasminogen activators.	Deamino Arginine Vasopressin	22-27	von Willebrand factor	Homo sapiens	61-64
8322282-1	1993	Although the vasopressin analogue desamino-d-arginine vasopressin (DDAVP) induces a very well characterized increase in factor VIII (FVIII), von Willebrand factor (vWF), tissue plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA), the mechanism(s) by which DDAVP enhances the plasma levels of these proteins is poorly understood.	Deamino Arginine Vasopressin	67-72	coagulation factor VIII	Homo sapiens	120-131
8322282-1	1993	Although the vasopressin analogue desamino-d-arginine vasopressin (DDAVP) induces a very well characterized increase in factor VIII (FVIII), von Willebrand factor (vWF), tissue plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA), the mechanism(s) by which DDAVP enhances the plasma levels of these proteins is poorly understood.	Deamino Arginine Vasopressin	67-72	coagulation factor VIII	Homo sapiens	133-138
8322282-1	1993	Although the vasopressin analogue desamino-d-arginine vasopressin (DDAVP) induces a very well characterized increase in factor VIII (FVIII), von Willebrand factor (vWF), tissue plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA), the mechanism(s) by which DDAVP enhances the plasma levels of these proteins is poorly understood.	Deamino Arginine Vasopressin	67-72	von Willebrand factor	Homo sapiens	141-162
8322282-1	1993	Although the vasopressin analogue desamino-d-arginine vasopressin (DDAVP) induces a very well characterized increase in factor VIII (FVIII), von Willebrand factor (vWF), tissue plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA), the mechanism(s) by which DDAVP enhances the plasma levels of these proteins is poorly understood.	Deamino Arginine Vasopressin	67-72	von Willebrand factor	Homo sapiens	164-167
8322282-1	1993	Although the vasopressin analogue desamino-d-arginine vasopressin (DDAVP) induces a very well characterized increase in factor VIII (FVIII), von Willebrand factor (vWF), tissue plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA), the mechanism(s) by which DDAVP enhances the plasma levels of these proteins is poorly understood.	Deamino Arginine Vasopressin	67-72	plasminogen activator, tissue type	Homo sapiens	170-204
8322282-1	1993	Although the vasopressin analogue desamino-d-arginine vasopressin (DDAVP) induces a very well characterized increase in factor VIII (FVIII), von Willebrand factor (vWF), tissue plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA), the mechanism(s) by which DDAVP enhances the plasma levels of these proteins is poorly understood.	Deamino Arginine Vasopressin	67-72	plasminogen activator, urokinase	Homo sapiens	210-246
8322282-1	1993	Although the vasopressin analogue desamino-d-arginine vasopressin (DDAVP) induces a very well characterized increase in factor VIII (FVIII), von Willebrand factor (vWF), tissue plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA), the mechanism(s) by which DDAVP enhances the plasma levels of these proteins is poorly understood.	Deamino Arginine Vasopressin	67-72	plasminogen activator, urokinase	Homo sapiens	248-252
8322282-5	1993	The second and third infusion of DDAVP induced a low response of FVIII and vWF.	Deamino Arginine Vasopressin	33-38	coagulation factor VIII	Homo sapiens	65-70
8322282-5	1993	The second and third infusion of DDAVP induced a low response of FVIII and vWF.	Deamino Arginine Vasopressin	33-38	von Willebrand factor	Homo sapiens	75-78
8322282-6	1993	In contrast, t-PA and u-PA exhibited a consistent response after each DDAVP infusion.	Deamino Arginine Vasopressin	70-75	plasminogen activator, tissue type	Homo sapiens	13-17
8322282-6	1993	In contrast, t-PA and u-PA exhibited a consistent response after each DDAVP infusion.	Deamino Arginine Vasopressin	70-75	plasminogen activator, urokinase	Homo sapiens	22-26
1377412-9	1992	We conclude that the increase in plasminogen activator activity upon the infusion of DDAVP results in the in vivo generation of plasmin, in the absence of coagulation activation.	Deamino Arginine Vasopressin	85-90	plasminogen	Homo sapiens	33-40
2510348-0	1989	DDAVP induces systemic release of urokinase-type plasminogen activator.	Deamino Arginine Vasopressin	0-5	plasminogen activator, urokinase	Homo sapiens	34-70
1742211-1	1991	Male Brattleboro rats with hereditary diabetes insipidus (BDI) were lifetime-treated with the vasopressin V2 receptor agonist desamino-8D-arginine vasopressin (DDAVP), given daily in the drinking fluid.	Deamino Arginine Vasopressin	160-165	arginine vasopressin receptor 2	Rattus norvegicus	94-117
2277161-12	1990	Treatment is suggested and consists of DDAVP (deamino 8-d-arginine vasopressin), which seems to be the most effective.	Deamino Arginine Vasopressin	39-44	arginine vasopressin	Homo sapiens	67-78
2632718-8	1989	Chronic dDAVP supplementation restored the body fluid pattern and the hypertensive response of the DOCA-salt-treated vasopressin-deficient rats.	Deamino Arginine Vasopressin	8-13	arginine vasopressin	Rattus norvegicus	117-128
2677861-5	1989	Management may be with deamino D arginine vasopressin (dDAVP) during gestation and postpartum since vasopressinase does not break down dDAVP.	Deamino Arginine Vasopressin	55-60	leucyl and cystinyl aminopeptidase	Homo sapiens	100-114
2510348-6	1989	We conclude that u-PA is released by DDAVP concurrently with t-PA and that it is presumably from the same origin as t-PA i.e. endothelial cells.	Deamino Arginine Vasopressin	37-42	plasminogen activator, urokinase	Homo sapiens	17-21
2510348-7	1989	u-PA and t-PA may therefore cooperate in the enhanced fibrinolytic activity upon DDAVP infusion.	Deamino Arginine Vasopressin	81-86	plasminogen activator, urokinase	Homo sapiens	0-4
2510348-7	1989	u-PA and t-PA may therefore cooperate in the enhanced fibrinolytic activity upon DDAVP infusion.	Deamino Arginine Vasopressin	81-86	plasminogen activator, tissue type	Homo sapiens	9-13
3129807-19	1988	DDAVP in several applications such as confirmation of haemostatic or fibrinolytic responsiveness in patient groups; for obtaining FVIII enriched plasma; as well as its obvious potential usefulness in home treatment of haemophilia A and von Willebrand"s disease.	Deamino Arginine Vasopressin	0-5	coagulation factor VIII	Homo sapiens	130-135
3257148-1	1988	When normal volunteers or patients with type I von Willebrand disease (VWD) are given desmopressin (DDAVP), a set of larger-than-normal (supranormal) von Willebrand factor (VWF) multimers, similar to those present in VWF-containing cells such as platelets megakaryocytes and endothelial cells, appear transiently in postinfusion plasma.	Deamino Arginine Vasopressin	100-105	von Willebrand factor	Homo sapiens	150-171
3257148-1	1988	When normal volunteers or patients with type I von Willebrand disease (VWD) are given desmopressin (DDAVP), a set of larger-than-normal (supranormal) von Willebrand factor (VWF) multimers, similar to those present in VWF-containing cells such as platelets megakaryocytes and endothelial cells, appear transiently in postinfusion plasma.	Deamino Arginine Vasopressin	100-105	von Willebrand factor	Homo sapiens	173-176
3257148-1	1988	When normal volunteers or patients with type I von Willebrand disease (VWD) are given desmopressin (DDAVP), a set of larger-than-normal (supranormal) von Willebrand factor (VWF) multimers, similar to those present in VWF-containing cells such as platelets megakaryocytes and endothelial cells, appear transiently in postinfusion plasma.	Deamino Arginine Vasopressin	100-105	von Willebrand factor	Homo sapiens	217-220
3111577-9	1987	After infusion of DDAVP, results indicated that, despite baseline results, SLE patients were able to respond to stimulation and the increase in PA activity produced a decrease in plasma fibrinogen levels.	Deamino Arginine Vasopressin	18-23	fibrinogen beta chain	Homo sapiens	186-196
3606814-0	1987	Vasopressin analogue (DDAVP) facilitates recall of narrative prose.	Deamino Arginine Vasopressin	22-27	arginine vasopressin	Homo sapiens	0-11
3536493-7	1986	When acquired central diabetes insipidus was present and urine output greater than 4 ml kg-1 h-1 desamino-cis-D-arginine vasopressin (DDAVP) was administered.	Deamino Arginine Vasopressin	134-139	arginine vasopressin	Homo sapiens	121-132
3085261-11	1986	The half-disappearance time of factor VIII and von Willebrand factor (vWF) after DDAVP ranged from five (factor VIII:C) to eight hours (vWF).	Deamino Arginine Vasopressin	81-86	von Willebrand factor	Homo sapiens	31-68
3085261-11	1986	The half-disappearance time of factor VIII and von Willebrand factor (vWF) after DDAVP ranged from five (factor VIII:C) to eight hours (vWF).	Deamino Arginine Vasopressin	81-86	von Willebrand factor	Homo sapiens	70-73
3080040-1	1986	1-D-Amino(8-D-arginine)-vasopressin (DDAVP) infusion in three patients with type IIa von Willebrand"s disease (vWD) resulted in a normalization of the factor VIII coagulant, factor VIII-related antigen, and von Willebrand factor (vWF) (ristocetin cofactor) activities and the bleeding time.	Deamino Arginine Vasopressin	37-42	von Willebrand factor	Homo sapiens	174-228
3080040-1	1986	1-D-Amino(8-D-arginine)-vasopressin (DDAVP) infusion in three patients with type IIa von Willebrand"s disease (vWD) resulted in a normalization of the factor VIII coagulant, factor VIII-related antigen, and von Willebrand factor (vWF) (ristocetin cofactor) activities and the bleeding time.	Deamino Arginine Vasopressin	37-42	von Willebrand factor	Homo sapiens	230-233
3938400-5	1985	The release of t-PA under the stimulus of DDAVP infusion overcame the postoperative shut-down of t-PA activity.	Deamino Arginine Vasopressin	42-47	plasminogen activator, tissue type	Homo sapiens	15-19
3938400-5	1985	The release of t-PA under the stimulus of DDAVP infusion overcame the postoperative shut-down of t-PA activity.	Deamino Arginine Vasopressin	42-47	plasminogen activator, tissue type	Homo sapiens	97-101
6494028-0	1984	Vasopressin analog (DDAVP) improves memory in human males.	Deamino Arginine Vasopressin	20-25	arginine vasopressin	Homo sapiens	0-11
4095258-10	1985	Studies with different intranasal dosages of 1-deamino-D-arginine-vasopressin (DDAVP) given once or twice a day showed that 20 micrograms effectively reduced urinary output and that administration once a day could be sufficient.	Deamino Arginine Vasopressin	79-84	arginine vasopressin	Homo sapiens	66-77
6430337-3	1984	In a series of double blind cross over studies on normal volunteers we have tested the effect of naloxone, DDAVP or saline on circulating levels of factor VIII related activities (VIIIR) and plasminogen activator (PA).	Deamino Arginine Vasopressin	107-112	cytochrome c oxidase subunit 8A	Homo sapiens	155-159
6494028-1	1984	One specific analog of arginine vasopressin, 1-desamine-8-D-arginine vasopressin (DDAVP), has been shown to improve learning and memory in humans.	Deamino Arginine Vasopressin	82-87	arginine vasopressin	Homo sapiens	32-43
6494028-1	1984	One specific analog of arginine vasopressin, 1-desamine-8-D-arginine vasopressin (DDAVP), has been shown to improve learning and memory in humans.	Deamino Arginine Vasopressin	82-87	arginine vasopressin	Homo sapiens	69-80
6249465-0	1980	[(Na-K) ATPase activity and corticopapillary osmotic gradient in the kidney of rats with hereditary hypothalamic diabetes insipudus after administration of 1-deamino-8-arginine-vasopressin (DDAVP)].	Deamino Arginine Vasopressin	190-195	arginine vasopressin	Rattus norvegicus	177-188
6300191-2	1983	AVP, oxytocin, and deamino-(8-D-arginine) vasopressin (dDAVP) affected prostaglandin biosynthesis in a rank order that parallels their pressor but not antidiuretic activity (AVP greater than oxytocin greater than dDAVP).	Deamino Arginine Vasopressin	213-218	arginine vasopressin	Homo sapiens	0-3
6300191-2	1983	AVP, oxytocin, and deamino-(8-D-arginine) vasopressin (dDAVP) affected prostaglandin biosynthesis in a rank order that parallels their pressor but not antidiuretic activity (AVP greater than oxytocin greater than dDAVP).	Deamino Arginine Vasopressin	213-218	arginine vasopressin	Homo sapiens	57-60
6638059-1	1983	Five members of a family with dominantly inherited diabetes insipidus were diagnosed and treated with deamino-d-arginine vasopressin (DDAVP), a vasopressin analogue given intranasally.	Deamino Arginine Vasopressin	134-139	arginine vasopressin	Homo sapiens	121-132
6798759-1	1981	DDAVP (l-desaminocysteine-(8-D-arginine)-vasopressin) produces a marked increase in plasma factor VIII procoagulant (F VIII:C) levels.	Deamino Arginine Vasopressin	0-5	arginine vasopressin	Homo sapiens	41-52
6798759-1	1981	DDAVP (l-desaminocysteine-(8-D-arginine)-vasopressin) produces a marked increase in plasma factor VIII procoagulant (F VIII:C) levels.	Deamino Arginine Vasopressin	0-5	coagulation factor VIII	Homo sapiens	117-123
427617-0	1979	[Long-term experience with 1-deamino-8-D-arginin vasopressin (DDAVP) treatment of children with diabetes insipidus centralis (author"s transl)].	Deamino Arginine Vasopressin	62-67	arginine vasopressin	Homo sapiens	49-60
706183-0	1978	[Possibilities in the determination of kidney concentrating ability as based on the DDAVP [deamino-(8-D-arginine)-vasopressin] test].	Deamino Arginine Vasopressin	84-89	arginine vasopressin	Homo sapiens	114-125
738214-1	1978	Thirty patients with central diabetes insipidus were treated with 1-deamino-9-D-arginine vasopressin (DDAVP) during the period of 3--10 years.	Deamino Arginine Vasopressin	102-107	arginine vasopressin	Homo sapiens	89-100
32040251-2	2021	DDAVP (1-deamino-8-D-arginine vasopressin) may reduce uremic bleeding but guidelines on its use are lacking.	Deamino Arginine Vasopressin	0-5	arginine vasopressin	Homo sapiens	30-41
30232300-0	2018	A case of ectopic ACTH syndrome due to DDAVP-sensitive but V1b receptor-negative bronchial typical carcinoid with lymphatic metastasis and plasma ProGRP elevation.	Deamino Arginine Vasopressin	39-44	proopiomelanocortin	Homo sapiens	18-22
29718707-9	2018	In cultured mouse collecting duct principal mCCDcl1 cells, expression of both Arg-II and AQP2 were enhanced by the vasopressin type 2 receptor agonist, desamino- d-arginine vasopressin (dDAVP).	Deamino Arginine Vasopressin	186-191	aquaporin 2	Mus musculus	89-93
29718707-10	2018	Silencing Arg-II enhanced the expression and membrane association of AQP2 by dDAVP without influencing cAMP levels.	Deamino Arginine Vasopressin	77-82	aquaporin 2	Mus musculus	69-73
30627311-4	2018	Treatment with a vasopressin analogue, desamino-D-arginine vasopressin (DDAVP) and forced intake of water restored plasma osmolality and serum sodium levels to normal.	Deamino Arginine Vasopressin	72-77	arginine vasopressin	Homo sapiens	59-70